108 related articles for article (PubMed ID: 32527549)
1. Evaluation of
Yu Q; Wang L; Ding J; Yang Z; Shou C; Zhao C; Zhu H
Bioorg Med Chem Lett; 2020 Jul; 30(14):127248. PubMed ID: 32527549
[TBL] [Abstract][Full Text] [Related]
2.
Zhu H; Zhao C; Liu F; Wang L; Feng J; Shou C; Yang Z
ACS Med Chem Lett; 2017 Feb; 8(2):266-269. PubMed ID: 28197324
[No Abstract] [Full Text] [Related]
3. Radiolabeling and evaluation of (64)Cu-DOTA-F56 peptide targeting vascular endothelial growth factor receptor 1 in the molecular imaging of gastric cancer.
Zhu H; Zhao C; Liu F; Wang L; Feng J; Zhou Z; Qu L; Shou C; Yang Z
Am J Cancer Res; 2015; 5(11):3301-10. PubMed ID: 26807312
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased
Feng J; Zhao C; Wang L; Qu L; Zhu H; Yang Z; An G; Tian H; Shou C
Theranostics; 2018; 8(8):2094-2106. PubMed ID: 29721065
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
6. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
8. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library.
An P; Lei H; Zhang J; Song S; He L; Jin G; Liu X; Wu J; Meng L; Liu M; Shou C
Int J Cancer; 2004 Aug; 111(2):165-73. PubMed ID: 15197767
[TBL] [Abstract][Full Text] [Related]
9. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.
Kumar SR; Deutscher SL
J Nucl Med; 2008 May; 49(5):796-803. PubMed ID: 18413389
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of (111)In-labeled macrocyclic chelator-amino acid derivatives for cancer imaging.
Lee JJ; Shetty D; Lee YS; Kim SE; Kim YJ; Hong MK; Son JY; Jeong JM
Nucl Med Biol; 2012 Apr; 39(3):325-33. PubMed ID: 22136890
[TBL] [Abstract][Full Text] [Related]
11. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
12. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis.
Jiang L; Miao Z; Kimura RH; Silverman AP; Ren G; Liu H; Lu H; Cochran JR; Cheng Z
J Biomed Biotechnol; 2012; 2012():368075. PubMed ID: 22570527
[TBL] [Abstract][Full Text] [Related]
13. Development of an inflammation imaging tracer,
Wei L; Petryk J; Gaudet C; Kamkar M; Gan W; Duan Y; Ruddy TD
J Nucl Cardiol; 2019 Aug; 26(4):1169-1178. PubMed ID: 29417414
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of
Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
[TBL] [Abstract][Full Text] [Related]
15. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
[TBL] [Abstract][Full Text] [Related]
17. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
18. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
19. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
